Biotech firms are turning to artificial intelligence to boost productivity and address talent shortages. Insilico Medicine is building a multi‑task AI platform that can generate disease hypotheses, design candidate molecules and even repurpose existing drugs, aiming to speed drug discovery and cut costs. GenEditBio is using AI to design engineered protein delivery vehicles that target specific tissues for in‑vivo CRISPR therapy, recently receiving FDA clearance for a corneal‑dystrophy trial. Both companies stress the need for richer, more diverse data to improve model accuracy and envision future tools such as digital twins for virtual clinical testing. Read more →

Researchers have introduced an artificial intelligence model, dubbed Evo, that learns from bacterial genomes to predict and complete protein-coding DNA. The system can reconstruct missing gene fragments, restore deleted genes in functional clusters, and even generate entirely new protein sequences, including toxin variants that lack known antitoxins. These capabilities suggest a powerful new tool for protein engineering and synthetic biology. Read more →